Specific niche view of the structured sector hierarchy. Useful for precedent work where broader sector slices include too much noise.
| Target | Buyer / Investor | Sector | Geo | Transaction size | EV / EBITDA |
|---|---|---|---|---|---|
| Personalis | Tempus AI | Biotechnology & Medical Research (NEC) | $361M – $489M | n/m | |
| Early Phase Services division of Worldwide Clinical Trials | Fortrea | Biotechnology & Medical Research (NEC) | $45.0M | 4× – 5× | |
| Worldwide Clinical Trials Early Phase Services division | Fortrea | Biotechnology & Medical Research (NEC) | $45.0M | 6× – 8× | |
| JPT Peptide Technologies GmbH | LEO III Fund, advised by DUBAG Group | Biotechnology & Medical Research (NEC) | $50.1M – $67.8M | 8× – 11× | |
| Precision Medicine Group, LLC | McKesson Corp. | Biotechnology & Medical Research (NEC) | $2,250M | 11× – 14× | |
| Colibri Scientific | Biofortuna | Biotechnology & Medical Research (NEC) | $26.0M – $35.0M | 8× – 11× | |
| New Zealand Clinical Research Group (NZCR) | Advent International | Biotechnology & Medical Research (NEC) | $600M | 11× – 14× | |
| Aker BioMarine ASA | Aker ASA | Biotechnology & Medical Research (NEC) | $24.0M – $32.0M | 11× – 14× | |
| InnoDiab Forschung GmbH | CERTANIA | Biotechnology & Medical Research (NEC) | $11.0M – $14.9M | 7× – 9× | |
| Plantae Biosciences | 80 Acres Farms | Biotechnology & Medical Research (NEC) | $120M | n/m |
Bins are observed deal frequencies across disclosed transactions. Use as a directional reference, not a target valuation.
Use the directory on the recent deals hub to switch between countries, sectors and sub-sectors. A free account unlocks the structured filters that go beyond the public view.